|
Glioma
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation is seen in melanoma, papillary thyroid carcinoma (including papillary thyroid carcinoma arising from ovarian teratoma), ovarian serous tumours, colorectal carcinoma, gliomas, hepatobiliary carcinomas and hairy cell leukaemia.
|
23594689 |
2013 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF alterations in pediatric low grade gliomas and mixed neuronal-glial tumors.
|
23612919 |
2013 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF alterations are key in certain low-grade gliomas and pediatric gliomas but rarely in high-grade gliomas in adults.
|
28271343 |
2017 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas.
|
27611946 |
2017 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Additionally, we show that activating BRAF mutations play a central role in both low and high grade glial tumors.
|
23592488 |
2013 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
CDKN2A, and PTEN in high-grade gliomas, followed by BRAF fusions in low-grade gliomas and H3F3A mutations in pediatric gliomas.
|
26681766 |
2016 |
|
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Development of selective inhibitors of BRAF has improved the survival of patients with melanoma and offers potential new therapeutic strategy in children with BRAF-mutant glioma.
|
27494648 |
2016 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
For colorectal carcinoma, thyroid cancer, malignant melanoma and gliomas BRAF V600E immunostaining is sufficient for screening purposes.
|
27350555 |
2016 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, a previous study on BRAF V600E mutation in paediatric glioma revealed a BRAF mutation in one of two tested DIAs/DIGs.
|
23822828 |
2014 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, it is unclear whether gliomas harboring BRAF mutations can be invariably regarded as these glioma subtypes or their derivatives.
|
27792249 |
2017 |
|
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this report, we highlight advances in Nf1-GEM modeling and review new experimental evidence that supports the emerging concept that Nf1- and KIAA1549:BRAF-induced gliomas arise from specific cell types in particular brain locations.
|
23624918 |
2014 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
One of our E-GBM patients with initial gross total resection quickly recurred within 4 months, required a second resection, and then was placed on vemurafenib; she remains tumor free 21 months after second resection without neuroimaging evidence of residual disease, adding to the growing number of reports of successful treatment of BRAF-mutated glial tumors with drug.
|
25581727 |
2015 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our data indicate that BRAF(V600E) is a common genetic alteration in low-grade glial tumors with neuronal component or differentiation.
|
25346165 |
2015 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our data support clinical evaluation of BRAF(V600E) and EGFR targeted therapy in treating BRAF(V600E) glioma.
|
26023796 |
2015 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Tandem duplications involving the BRAF kinase gene have recently been identified as the most frequent genetic alteration in sporadic pediatric glioma, creating a novel fusion protein (f-BRAF) with increased BRAF activity.
|
23152448 |
2012 |
|
Glioma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF<sup>V600E</sup>/TERT promoter double-mutated glioma.
|
31391125 |
2019 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The BRAF mutation V600E is critical to the pathogenesis of 10-20% of pediatric gliomas, and a small proportion of adult HGGs.
|
26384810 |
2016 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The aim of our study is to investigate the potential use of BRAF mutations on prognosis of glioma patients.
|
28534272 |
2018 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The case emphasizes the importance of comprehensive assessment based on pathological, genetic and clinical findings and calls for further investigations of non-diffuse glioma with H3F3A K27M and glioma with H3F3A K27M and BRAF V600E.
|
31254135 |
2019 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The growth inhibitory effects of UAI-201 correlated with the BRAF-V600E genotype of the glioma cell lines.
|
24721513 |
2014 |
|
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to clarify the incidence of B-RAF mutations and their possible relation with tumor progression in a series of 82 human gliomas, including 49 astrocytic and 33 oligodendroglial tumors.
|
15791479 |
2005 |
|
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The researchers have started a second trial for patients with glioma and other BRAF-mutant tumor types, this time evaluating dabrafenib combined with trametinib.
|
28062673 |
2017 |
|
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The use of poly(adenosine 5'-diphosphate-ribose) inhibitors may be another way of specifically targeting IDH-mutant gliomas in addition to specific inhibitors, demethylating agents and anti-IDH vaccines. v-raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutant anaplastic xanthoastrocytomas and gangliogliomas may benefit from BRAF and mitogen-activated protein kinase inhibitors.
|
28901965 |
2017 |
|
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The work from Wang and colleagues identifies an acquired secondary BRAF mutation that confers resistance to pharmacologic BRAF inhibition in a BRAF<sup>V600E</sup> glioma.
|
30181170 |
2018 |